Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: Experimental study in rats

International Urology and Nephrology

Volumn 43, Issue 1, 2011, Pages 39-45

  Fornari, Alexandre ^a   Rhoden, Ernani Luis ^a   Zettler, Cláudio G ^a   Ribeiro, Eduardo P ^b   Rhoden, Claudia R ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Benign prostatic hyperplasia; Doxazosin; Finasteride; Histology; Prostate; Rats

Indexed keywords

DOXAZOSIN; DOXAZOSIN MESYLATE; FINASTERIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL STUDY; HISTOPATHOLOGY; LONG TERM CARE; MALE; MORPHOMETRICS; MUSCLE CELL; NONHUMAN; ORGAN WEIGHT; PROSTATE; PROSTATE EPITHELIUM; PROSTATE VENTRAL LOBE; RAT; SMOOTH MUSCLE;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FINASTERIDE; FOLLOW-UP STUDIES; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953835720     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-010-9770-3     Document Type: Article

References (18)

1. Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ et al (1998) Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 159:878-882 (Pubitemid 28106549)
2. Blom JH, Schroder FH (1992) Epidemiology and natural course of benign prostatic hyperplasia. Urologe A 31: 129-134
3. Berry SJ, Coffey DS, Walsh PC et al (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479 (Pubitemid 14026148)
4. Sagnier PP, MacFarlane G, Richard F et al (1994) Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 151:1266-1270
5. McDonald H, Hux M, Brisson M et al (2004) An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 11:2327-2340
6. McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-2398 (Pubitemid 37542987)
7. Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179(2):616-621
8. Fitzpatrick JM, Kirby RS (2004) Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice? BJU Int 93:914-915
9. Kyprianou N (2003) Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169:1520-1525
10. Coffey DS, Walsh PC (1990) Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17:461-475 (Pubitemid 20220190)
11. Dutkiewics S (2001) Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 32(3):423-432
12. Marks LS, Partin AW, Gormley GJ et al (1997) Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 157:2171-2178 (Pubitemid 27208666)
13. Bruskewitz R, Girman CJ, Fowler J et al (1999) Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS study group. Proscar long-term efficacy and safety study. Urology 54:670-678
14. Turkeri LN, Ozyurek M, Ersev D et al (2001) A Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia. Arch Esp Urol 54:191-196 (Pubitemid 32289566)
15. Justulin LA Jr, Delella FK, Felisbino SL (2008) Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobes. Cell Tissue Res 332(1):171-183
16. Erdogru T, Ciftcioglu MA, Emreoglu I et al (2002) Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urol Int 69:287-292 (Pubitemid 35365383)
17. Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N (2001) Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 46:45-51 (Pubitemid 32157775)
18. Canda AE, Mungan MU, Yilmaz O et al (2006) Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol 38(2): 275-280 (Pubitemid 44138153)